Genomic DNA regulatory elements controlling BCL11A expression (BCL11A erythroid-specific enhancer) (BCL11A erythroid enhancer)

The genomic DNA regulatory elements controlling BCL11A expression, specifically the erythroid-specific enhancer located in the second intron of the BCL11A gene (often termed the +58 kb enhancer), serve as a critical molecular switch for hemoglobin production [1, 7]. BCL11A is a transcription factor that acts as a potent repressor of the gamma-globin genes, thereby silencing the production of fetal hemoglobin (HbF) after birth [2, 5]. By targeting this specific enhancer rather than the BCL11A protein-coding sequence, therapeutic interventions can selectively downregulate BCL11A in the erythroid lineage while preserving its essential roles in B-cell development and neuronal function [4, 8]. This target is the focus of the first FDA-approved CRISPR-based gene therapy, exagamglogene autotemcel, which treats sickle cell disease and transfusion-dependent beta-thalassemia [3, 5]. The therapy utilizes CRISPR-Cas9 to disrupt the GATA1 transcription factor binding site within the enhancer, leading to reduced BCL11A levels and the reactivation of HbF [1, 6]. The resulting increase in HbF compensates for defective or missing adult beta-globin, effectively preventing red blood cell sickling and improving oxygen transport [3, 4]. Safety considerations for targeting these regulatory elements include the potential for off-target genomic edits and the long-term stability of the modified hematopoietic stem cell population [9].

Other names

BCL11A erythroid-specific enhancerBCL11A +58 kb enhancerBCL11A intronic enhancerGATA1-binding site at the +58 BCL11A erythroid enhancerBCL11A erythroid-specific DNase I hypersensitive siteBCL11A +55 kb enhancer

CRISPR-Cas9 mediated disruption of the erythroid-specific enhancer (specifically the GATA1 binding site) to reduce BCL11A expression in erythroid cells, which derepresses gamma-globin and increases fetal hemoglobin (HbF) production [1, 3, 6].